Literature DB >> 23960735

Attitude and perception of patients and health care practitioners toward oral sustained release dosage forms in Palestine.

Abdel Naser Zaid1.   

Abstract

AIM: To evaluate the knowledge of health professionals in Palestine regarding the advantages of sustained release dosage forms (SRDFs) over conventional therapy.
METHODS: Data were gathered from a questionnaire that was handed out to community pharmacists, physicians and patients. Pharmaceutical industry decision makers were enrolled in this study. Data were analyzed using the SPSS.
RESULTS: Pharmacists (92.9%) and 89.2% of physicians thought that SRDFs improve patient compliance. 81.5% of pharmacists and 77% of physicians were in agreement regarding the capacity of SRDFs to maintain therapeutic activity during night. In this study, 81.5% of pharmacists and 81% of physicians believed that SRDFs provide further advantage with psychiatric patients who forget to take their medications. Pharmacists (63.1%) and only 63.5% of physicians believed that SRDFs yield a time saving for nurses who use SRDFs in hospital. Only 45.3% of physicians and 43.4% of pharmacists thought that SRDFs result in cost saving due to better disease management. Pharmacists (95.2%) and 95.9% of physicians agreed that SRDFs could be the right choice for faith patient's who must take their medication during the month of Ramadan. Pharmacists (66.7%) and 50.7% of physicians recognize that SRDFs may be unsafe if they are improperly formulated. Bad swallowing was also recognized as inconveniences of SRDFs by 67.9% of pharmacists and 57.3% of physicians. Given the above advantages, 75% of patients showed economical problems regarding the cost of the single course therapy of SRDFs and 100% of interviewed patients were enthusiastic about the advantage of SRDFs during Ramadan.
CONCLUSION: The advantages of SRDFs are not completely understood by Palestinian health professionals. Pharmaceutical industries should pay more attention to the development and advertising of SRDFs due to the valuable advantages of these dosage forms.

Entities:  

Keywords:  Patient compliance; Ramadan; Sustained release dosage forms

Year:  2010        PMID: 23960735      PMCID: PMC3731029          DOI: 10.1016/j.jsps.2010.07.005

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  12 in total

1.  "Avoid the crush": hazards of medication administration in patients with dysphagia or a feeding tube.

Authors:  Patricia Cornish
Journal:  CMAJ       Date:  2005-03-29       Impact factor: 8.262

2.  Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation.

Authors:  D Stepensky; M Friedman; W Srour; I Raz; A Hoffman
Journal:  J Control Release       Date:  2001-03-12       Impact factor: 9.776

3.  Efficacy, safety and tolerance of oral sustained-release ritodrine given after intravenous administration in the treatment of premature labor.

Authors:  A van Assche; H Thoumsin; B Hendrickx
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1990-03       Impact factor: 2.435

4.  Patients' evaluation of shape, size and colour of solid dosage forms.

Authors:  A B Overgaard; J Højsted; R Hansen; J Møller-Sonnergaard; L L Christrup
Journal:  Pharm World Sci       Date:  2001-10

5.  [The passage time for capsules and tablets through the esophagus].

Authors:  H Hey; K Sørensen; F B Jørgensen; H Hasselbalch; T Wamberg
Journal:  Ugeskr Laeger       Date:  1983-08-08

Review 6.  Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate.

Authors:  P Genton
Journal:  Acta Neurol Scand Suppl       Date:  2005

Review 7.  Advances in psychotropic formulations.

Authors:  Samuel Keith
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-05-06       Impact factor: 5.067

8.  [Problems when swallowing tablets. A questionnaire study from general practice].

Authors:  O Andersen; O K Zweidorff; T Hjelde; E A Rødland
Journal:  Tidsskr Nor Laegeforen       Date:  1995-03-20

9.  Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.

Authors:  Alexandra Ward; Duygu Bozkaya; Jochen Fleischmann; Dominique Dubois; Rainer Sabatowski; J Jaime Caro
Journal:  Curr Med Res Opin       Date:  2007-10       Impact factor: 2.580

10.  Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.

Authors:  Martin Hale; Iulia Cristina Tudor; Sarita Khanna; John Thipphawong
Journal:  Clin Ther       Date:  2007-05       Impact factor: 3.393

View more
  2 in total

1.  Three-Dimensional (3D)-Printed Zero-Order Released Platform: a Novel Method of Personalized Dosage Form Design and Manufacturing.

Authors:  Dongyang Fang; Yining Yang; Mengsuo Cui; Hao Pan; Lijie Wang; Pingfei Li; Wenjing Wu; Sen Qiao; Weisan Pan
Journal:  AAPS PharmSciTech       Date:  2021-01-06       Impact factor: 3.246

2.  Knowledge about the administration and regulation of high alert medications among nurses in Palestine: a cross-sectional study.

Authors:  Sa'ed H Zyoud; Samar M Khaled; Baraa M Kawasmi; Ahed M Habeba; Ayat T Hamadneh; Hanan H Anabosi; Asma'a Bani Fadel; Waleed M Sweileh; Rahmat Awang; Samah W Al-Jabi
Journal:  BMC Nurs       Date:  2019-03-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.